Fred Saad, MD, FRCS, CQ, FCAHS

Fred Saad, MD, FRCS, CQ, FCAHS

University of Montreal Hospital Center

Montreal, Quebec, Canada

Fred Saad, MD, FRCS, CQ, FCAHS is a Professor and Chairman of the Department of Surgery at the University of Montréal in Quebec, Canada. Dr. Saad also holds the Raymond Garneau Chair in Prostate Cancer Research and is the Director of Clinical Research and the Molecular Oncology Research Laboratory in Prostate Cancer at the University of Montréal. His research interests include novel therapeutics in prostate cancer, molecular prognostic markers, and mechanisms of progression. He has over 40 clinical and basic research projects ongoing and has received over 50 million in research grants. Prof. Saad currently sits on over 15 steering committees of international clinical trials and serves on several guideline committees.   

Dr. Saad is also the Principal Investigator at the Alliance-Procure biobank; President of the Canadian Urologic Oncology Group and the National Cancer Institute of Canada; a member of the Board of Directors of the Montréal Cancer Institute, the National Cancer Institute of Canada, and the Procure Alliance; and Secretary of the Canadian Prostate Health Council and Global G-U. Dr. Saad has played a leadership role and been a co-author on many of the practice-changing clinical trials and publications in advanced prostate cancer over the last 20 years. Dr. Saad presently sits on 7 steering committees of ongoing international clinical trials and serves on several guideline committees. He is a member of several editorial boards, including Lancet Oncology, JAMA Oncology, Nature Reviews Urology, Genitourinary Cancer, and Urology. He has published over 1,000 peer-reviewed articles, 50 book chapters, and 8 books, including Understanding Prostate Cancer, which is designed for patients and has sold over 250,000 copies to date. With an h-factor of 108 and over 70,000 citations, he is listed as one of the world’s most cited clinician-scientists. His numerous awards include the lifetime achievement award from the CHUM Research Center and the Lifetime Achievement Award from the Quebec Urologic Association. In 2018, Dr. Saad was named a Knight of The National Order of Quebec, the highest honor given by the Quebec government.

Talks by Fred Saad, MD, FRCS, CQ, FCAHS

Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score

Fred Saad, MD, FRCS, presents findings from an exploratory analysis he led and presented at the American Urological Association’s 2019 Annual Meeting. The study evaluated the association between DECIPHER genomic classifier (GC) score and metastasis-free survival following apalutamide treatment in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients included in the SPARTAN study.

Read More